Scripps Clinic and Research Foundation

The Scripps Research Institute

Rorer Biotechnology Inc.

Other

Theodore S Zimmerman

Carol A Fulcher

Paul A Foster

Richard Allen Houghten

William N Drohan

Zaverio M Ruggeri

Dorothea H Scandella

Yoshihiro Fujimura

Polypeptides have been discovered which exhibit high specific VIII:C coagulant activity. Monoclonal antibodies to the polypeptides are also disclosed.

Factor VIII coagulant polypeptides and monoclonal antibodies to them

Peptides which inhibit the binding of yon Willebrand Factor to Factor VIII. Monoclonal antibodies capable of specifically binding to the region of von Willebrand Factor containing the Factor VIII binding domain. Improved methods of preparing Factor VIII.

Factor VIII binding domain of von Willebrand factor

Fragments of Factor VIII:C polypeptide have been discovered which exhibit highly specific factor VIII activity. Monoclonal antibodies to the polypeptide fragments and methods for the isolation and purification of said fragments are also disclosed.

Factor VIII coagulant polypeptides: method of making

Peptides which inhibit the binding of von Willebrand Factor to Factor VIII. Monoclonal antibodies capable of specifically binding to the region of von Willebrand Factor containing the Factor VIII binding domain. Improved methods of preparing Factor VIII.

Factor VIII binding domain of von Willebrand Factor

This invention provides a peptide fragment of human von Willebrand Factor (vWF) and sub-fragment thereof isolated as enzymtic digestion products from naturally occurring human vWF, or isolated from synthetic peptide mixtures or isolated from lysates of organisms capable of producing recombinant human vWF. The fragments and sub-fragments are useful in the prevention and treatment of cardiovascular disorders by virtue of their ability to inhibit the binding of vWF to platelets, heparin and/or collagen.

Peptides that inhibit von Willebrand Factor binding to the platelet SPIB

Fragments of the factor VIII:C polypeptide have been discovered which exhibit highly specific factor VIII activity. Monoclonal antibodies to the polypeptide fragments and methods for the isolation and purification of said fragments are also disclosed.

Factor VIII coagulant polypeptides

New fragments of the Factor VIII procoagulant protein (Factor VIIIC) are disclosed. These fragments have an Mr value of 88,000 d or 49,000 d or extend from amino acid residues 1974 to 2332 or 2052 to 2332. These fragments have use in the treatment of patients who have developed antibodies which inhibit Factor VIII.

Recombinant Factor VIIIC fragments

A linear accelerator mounted on a launcher that injects propellant into a launcher behind a projectile causing the projectile to achieve greater distances. The launcher has apertures along its longitudinal surface allowing propellant to enter the inner cavity of the launcher. When the projectile is fired, additional propellant is introduced behind the projectile giving it additional impetus.

Linear accelerator

A method of recovering active, highly purified and concentrated vitamin K-dependent proteins from plasma, concentrate or mixtures of proteins produced by recombinant DNA technology using an immuno adsorbent comprising a monoclonal antibody.

Ultrapurification of factor IX and other vitamin K-dependent proteins

Protein fragments containing Factor VIII binding domain of von

Recombinant factor VIIIC derived fragments

Active factor VIII:C coagulant polypeptides identified by partial amino acid sequences are disclosed.

Factor VIII coagulant polypeptides and monoclonal antibodies tof them

The present invention is a protein purification column comprising an organic substrate matrix having low reactivity to proteins, said matrix being capable of maintaining monoclonal antibodies attached thereto in an external configuration and preventing interaction with the protein to be bound to the antibody, and a monoclonal antibody attached to the substrate, the monoclonal antibody having a specific affinity for the protein to be isolated. The present invention also is a method for isolating and purifying specific protein from a solution, wherein

Growing community of inventors

La Jolla, CA, United States of America

Theodore S Zimmerman